World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company’s lead Phase 3 asset, new indications, and pipeline expansion

世界著名科学家和临床医生提供专家见解和建议，以支持公司领先的第三阶段资产、新适应症和管道扩张的发展

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice..

加利福尼亚州南旧金山——（商业新闻短讯）——昆斯治疗公司（Nasdaq:QNCX）是一家晚期生物技术公司，开发了一种创新的药物输送技术，利用患者自身的生物学特性来提供罕见疾病治疗剂，今天宣布成立一个科学咨询委员会（SAB），该委员会由生物化学，神经病学，免疫学，血液学，药理学和临床实践。。

“We are pleased to announce the formation of our Scientific Advisory Board to support Quince in our scientific and medical programs,” said Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer. “We have assembled a highly distinguished group of scientific and clinical thought leaders who are uniquely positioned to provide deep insights and advice, including to support the advancement of our Phase 3 lead asset, EryDex, for the potential treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia.”.

昆斯首席执行官兼首席医疗官、医学博士德克·塞耶（DirkThye）表示：“我们很高兴宣布成立科学顾问委员会，支持昆斯的科学和医学项目。”。“我们汇集了一批杰出的科学和临床思想领袖，他们具有独特的地位，可以提供深入的见解和建议，包括支持我们的第三阶段领先资产EryDex的发展，以潜在治疗罕见的神经退行性疾病共济失调毛细血管扩张症。”。

Dr. Mauro Magnani, Ph.D., Chair of Quince’s Scientific Advisory Board, said, “Quince’s AIDE technology is designed to harness the power of a patient’s own red blood cells to optimize the pharmacokinetics and biodistribution of a therapeutic and deliver sustained treatment. I look forward to collaborating with the renowned members of Quince’s management team, Board of Directors, and Scientific Advisory Board to support the company’s mission to bring its innovative drug delivery technology to patients living with rare diseases.”.

昆斯大学科学顾问委员会主席毛罗·马格纳尼博士说，（笑声）“Quince的AIDE技术旨在利用患者自身红细胞的力量，优化治疗药物的药代动力学和生物分布，并提供持续的治疗。我期待着与Quince管理团队、董事会和科学顾问委员会的知名成员合作，以支持该公司实现创新的使命e为患有罕见疾病的患者提供药物输送技术。”。

Quince’s newly formed SAB includes the following seven founding members:

昆斯新成立的SAB包括以下七名创始成员：

Mauro Magnani, Ph.D., Chair of the SAB, is a Professor of Biochemistry at the University of Urbino, Italy and is a co-founder of Quince’s proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform. Dr. Magnani developed and patented a method for using autologous red blood cells that allow for the slow delivery of different drugs in circulation to treat patients in need.

Mauro Magnani博士，SAB主席，意大利乌尔比诺大学生物化学教授，Quince专有自体细胞内药物包封（AIDE）技术平台的联合创始人。Magnani博士开发并获得了一种使用自体红细胞的方法的专利，该方法允许在循环中缓慢输送不同的药物以治疗需要的患者。

His areas of interest and current research include red blood cells as drug delivery systems and as circulating bioreactors, development and delivery of biologics, and nanomaterials in drug delivery and imaging. Dr. Magnani has authored more than 500 papers published in international peer-reviewed scientific journals, holds 16 patents, and has co-edited three books, in addition to serving as an editorial board member for several biomedical journals and referee for different international scientific institutions.

他感兴趣的领域和当前的研究包括红细胞作为药物输送系统和循环生物反应器，生物制剂的开发和输送，以及药物输送和成像中的纳米材料。Magnani博士在国际同行评审的科学期刊上发表了500多篇论文，拥有16项专利，并共同编辑了三本书，此外还担任了多家生物医学期刊的编辑委员会成员和不同国际科学机构的裁判。

He is a member of the National Committee for Biotechnology, Presidency of the Italian Government, and an Italian delegate at the Organization for Economic Cooperation and Development and at the European Commission. Dr. Magnani received a Ph.D. in Biochemistry from the University of Urbino, Italy..

他是国家生物技术委员会成员、意大利政府主席，也是经济合作与发展组织和欧盟委员会的意大利代表。Magnani博士获得了意大利乌尔比诺大学生物化学博士学位。。

Carlo Brugnara, M.D., is a Professor of Pathology at Harvard Medical School and Director of the Hematology Laboratory at Boston Children’s Hospital. Dr. Brugnara’s clinical laboratory-based research has focused on the use of hematological parameters to assess the balance between iron availability and erythropoiesis.

卡罗·布鲁格拉医学博士是哈佛医学院病理学教授，波士顿儿童医院血液学实验室主任。Brugnara博士基于临床实验室的研究集中在使用血液学参数来评估铁可用性和红细胞生成之间的平衡。

He has described the appearance of functional iron deficiency in normal subjects treated with recombinant human erythropoietin (r-HuEPO) based on the particular flow cytometric characteristics of erythrocytes and reticulocytes. Dr. Brugnara also has shown the clinical value of reticulocyte parameters in the setting of r-HuEPO use and in the diagnosis of iron deficiency in children.

他描述了基于红细胞和网织红细胞的特定流式细胞术特征，用重组人促红细胞生成素（r-HuEPO）治疗的正常受试者出现功能性铁缺乏症。Brugnara博士还显示了网织红细胞参数在使用r-HuEPO和诊断儿童缺铁中的临床价值。

He is a fellow of the American Society of Clinical Investigation, the Association of American Physicians, and the Academy of Clinical Laboratory Physicians and Scientists, in addition to serving as the Editor-in-Chief of the American Journal of Hematology. He received his M.D. from the University of Verona, Italy and completed his postdoctoral fellowship at the laboratory of Dr.

他是美国临床研究学会、美国医师协会、临床实验室医师和科学家学会的研究员，此外还担任《美国血液学杂志》的主编。他在意大利维罗纳大学获得了医学博士学位，并在博士实验室完成了博士后研究。

Daniel Tosteson in the Department of Physiology at Harvard Medical School. Dr. Brugnara also trained in Clinical Pathology and Transfusion Medicine at Brigham and Women’s Hospital in Boston and holds board certifications in both specialties..

哈佛医学院生理学系的丹尼尔·托斯特森（DanielTosteson）。Brugnara博士还曾在波士顿的Brigham and Women's Hospital接受过临床病理学和输血医学方面的培训，并持有这两个专业的董事会认证。。

William Jusko, Ph.D., is a State University of New York Distinguished Professor of Pharmaceutical Sciences at the Buffalo University Jacobs School of Medicine and Biomedical Sciences. Dr. Jusko’s research interests are in theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents, including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer.

William Jusko博士是纽约州立大学布法罗大学雅各布斯医学与生物医学科学学院药学杰出教授。Jusko博士的研究兴趣是各种免疫抑制剂（包括皮质类固醇）以及用于治疗糖尿病，炎症和癌症的药物的药代动力学和药效学的理论，基础和临床方面。

His research expertise includes the diverse effects of corticosteroids and he has evolved advanced mathematical models of receptor/gene-mediated responses. Dr. Jusko has developed mechanism-based pharmacokinetic, pharmacodynamic, and disease progression models and computational methods describing the action of various drugs and utilizes mathematical models of drug action to determine optimal dosage regimens.

他的研究专长包括皮质类固醇的多种作用，他已经发展出受体/基因介导反应的先进数学模型。Jusko博士开发了基于机制的药代动力学，药效学和疾病进展模型以及描述各种药物作用的计算方法，并利用药物作用的数学模型来确定最佳剂量方案。

He has authored more than 600 publications, is a fellow of several societies, serves on the editorial boards of seven journals, and is the former Editor-in-Chief of the Journal of Pharmacokinetics & Pharmacodynamics. Dr. Jusko received a Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo..

他撰写了600多篇出版物，是多个协会的会员，在七种期刊的编辑委员会任职，并且是《药代动力学与药效学杂志》的前主编。Jusko博士获得纽约州立大学布法罗分校药学博士学位。。

Howard Lederman, M.D., Ph.D., is a Professor of Pediatrics at the Johns Hopkins University School of Medicine and Director of the Immunodeficiency Clinic, the Pediatric Immunology Laboratory, and the Ataxia-Telangiectasia (A-T) Clinical Center at Johns Hopkins Medical Center. Dr. Lederman specializes in the evaluation, diagnostic testing, and long-term management of patients of all ages who have known or suspected primary immunodeficiency diseases.

霍华德·莱德曼医学博士是约翰·霍普金斯大学医学院的儿科教授，也是约翰·霍普金斯医学中心免疫缺陷诊所、儿科免疫学实验室和共济失调毛细血管扩张症（a-T）临床中心的主任。莱德曼博士专门从事对已知或疑似原发性免疫缺陷疾病的所有年龄段患者的评估、诊断测试和长期管理。

Considered one of the world’s leading experts in the rare neurodegenerative disease A-T, Dr. Lederman’s current laboratory and clinical research focuses on better understanding and treating A-T patients, and will participate as an investigator in Quince’s upcoming Phase 3 clinical trial of its lead asset, EryDex.

莱德曼博士被认为是罕见神经退行性疾病A-T的世界领先专家之一，目前的实验室和临床研究侧重于更好地了解和治疗A-T患者，并将作为研究者参与昆斯即将进行的其主要资产EryDex的3期临床试验。

He is a member of numerous professional societies, including the American Association of Immunologists, the American Society for Microbiology, and the Clinical Immunology Society. Dr. Lederman received a M.D. and Ph.D. from the University of Michigan Medical School and completed a residency in pediatrics at Johns Hopkins Children’s Center and a fellowship in immunology at the Hospital for Sick Children in Toronto.

他是众多专业协会的成员，包括美国免疫学家协会、美国微生物学会和临床免疫学会。莱德曼博士获得了密歇根大学医学院的医学博士和博士学位，并在约翰·霍普金斯儿童中心完成了儿科住院治疗，并在多伦多病童医院获得了免疫学奖学金。

He is board certified by the American Board of Pediatrics..

他是美国儿科委员会认证的董事会。。

Vladimir Muzykantov, M.D., Ph.D., is a Founders Professor of Nanoparticle Research at the University of Pennsylvania, Philadelphia (UPENN), Professor and Vice-Chair of the Department of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine, UPENN, and Founding Director of the Center for Translational Targeted Therapeutics and Nanomedicine, UPENN.

医学博士弗拉基米尔·穆兹坎托夫（VladimirMuzykantov）是宾夕法尼亚大学费城分校（UPENN）纳米粒子研究的创始人教授，UPENN佩雷尔曼医学院系统药理学和转化治疗学系教授兼副主任，UPENN转化靶向治疗和纳米医学中心创始主任。

Dr. Muzykantov conducts research in drug/gene targeting in the vascular system, including devising drug delivery systems for precise molecular interventions in the lungs, heart, brain, spleen, and other organs and blood components, including host defense agents. Since the early 1980s, he has explored red blood cells as natural carriers for prolonged circulation and site-specific delivery of drugs aimed at regulation of bleeding, clotting, thrombolysis, inflammation, and complement.

Muzykantov博士在血管系统中进行药物/基因靶向研究，包括设计药物输送系统，以对肺，心脏，大脑，脾脏以及其他器官和血液成分（包括宿主防御剂）进行精确的分子干预。自20世纪80年代初以来，他一直在探索红细胞作为天然载体，用于延长血液循环和特定部位的药物输送，旨在调节出血，凝血，溶栓，炎症和补体。

He also investigates the mechanisms controlling drug delivery at the level of whole organism to nanoscale regulation of intracellular targeting/trafficking of drugs. He holds a portfolio of intellectual property, including about 40 patents and disclosures, and has authored more than 280 publications.

他还研究了在整个生物体水平上控制药物输送的机制，以纳米级调节细胞内靶向/贩运药物。他拥有一系列知识产权，包括约40项专利和披露，并撰写了280多篇出版物。

Dr. Muzykantov was elected as a co-Chair of the Gordon Research Conference on Drug Carriers and was a recipient of the Established Investigator Award and Bugher Stroke Award from the American Heart Association. He received a M.D. in Internal Medicine from the First Moscow Medical School and a Ph.D. in Biochemistry from the Russian National Cardiology Research Center in Moscow..

Muzykantov博士被选为Gordon药物携带者研究会议的联合主席，并获得了美国心脏协会设立的研究者奖和Bugher中风奖。他获得了莫斯科第一医学院的内科医学博士学位和莫斯科俄罗斯国家心脏病学研究中心的生物化学博士学位。。

Susan Perlman, M.D., is a Clinical Professor in the Department of Neurology at the David Geffen School of Medicine at the University of California, Los Angeles and Director of the UCLA Ataxia and Neurogenetics Clinical Trials Programs and Post-Polio Program. Leveraging three decades as a clinical professor of Neurology, Dr.

医学博士苏珊·帕尔曼（SusanPerlman）是加州大学洛杉矶分校大卫·格芬医学院神经病学系的临床教授，也是加州大学洛杉矶分校共济失调和神经遗传学临床试验项目以及脊髓灰质炎后项目的主任。利用三十年神经病学临床教授的经验，Dr。

Perlman is an expert in building subspecialty clinics that diagnose and treat patients living with rare, progressive, and incurable disorders, including Friedreich’s ataxia, Huntington’s disease, and all types of genetic and non-genetic cerebellar ataxias, such as A-T. She has long been a site primary investigator for Friedreich's ataxia trials, sits on the Medical Advisory Board of the National Ataxia Foundation, and will participate as an investigator in Quince’s upcoming Phase 3 clinical trial of its lead asset, EryDex.

Perlman是建立亚专科诊所的专家，该诊所可诊断和治疗患有罕见，进行性和不可治愈疾病的患者，包括弗里德里希共济失调，亨廷顿舞蹈病以及所有类型的遗传性和非遗传性小脑共济失调，如A-T。她长期以来一直是弗里德里希共济失调试验的现场主要研究者，担任国家共济失调基金会医学顾问委员会成员，并将作为研究人员参与Quince即将进行的主要资产EryDex的3期临床试验。

Dr. Perlman currently oversees four natural history studies and serves as an investigator for numerous clinical trials as she works to spearhead the development of disease-modifying therapies to address the significant unmet needs in rare disease. She began her specialty work in chronic diseases of the neuromuscular system, including muscular dystrophy, spinal cord diseases, and cerebral palsy.

帕尔曼博士目前负责四项自然史研究，并担任多项临床试验的研究者，她致力于带头开发疾病缓解疗法，以解决罕见疾病中尚未满足的重大需求。她开始从事神经肌肉系统慢性疾病的专业工作，包括肌肉萎缩症，脊髓疾病和脑瘫。

Dr. Perlman was awarded the Sherman M. Mellinkoff Faculty Award at the Hippocratic Oath ceremony of the graduating class of 2008, which is considered the highest faculty distinction at the David Geffen School of Medicine. She received a M.D. from the Renaissance School of Medicine at Stony Brook University and completed a residency in Neurology and a two-year Muscular Dystrophy Association fellowship in Neurology at the University of California, Los Angeles..

帕尔曼博士在2008年毕业班的希波克拉底宣誓仪式上获得了谢尔曼·M·梅林柯夫（ShermanM.Mellinkoff）教师奖，这被认为是戴维·格芬医学院（DavidGeffen School of Medicine）最高的教师荣誉。她获得了石溪大学文艺复兴医学院的医学博士学位，并在加利福尼亚大学洛杉矶分校完成了神经病学住院医师和为期两年的肌肉萎缩症协会神经病学奖学金。。

James Spudich, Ph.D., is the Douglass M. and Nola Leishman Professor of Cardiovascular Disease in the Department of Biochemistry at the Stanford University School of Medicine. Over the last five decades, the Spudich laboratory studied the structure and function of the myosin family of molecular motors in vitro and in vivo, and they developed multiple new tools, including in vitro motility assays taken to the single molecule level using laser traps.

詹姆斯·斯普迪奇博士是斯坦福大学医学院生物化学系的道格拉斯·M·和诺拉·利什曼心血管疾病教授。在过去的五十年中，Spudich实验室在体外和体内研究了肌球蛋白家族分子马达的结构和功能，并开发了多种新工具，包括使用激光陷阱进行单分子水平的体外运动测定。

That work led to his laboratory’s current focus at Stanford on the human cardiac sarcomere and the molecular basis of hypertrophic and dilated cardiomyopathy. Dr. Spudich postulated in 2015 that a majority of hypertrophic cardiomyopathy mutations are likely to be shifting beta-cardiac myosin heads from a sequestered off-state to an active on-state for interaction with actin, resulting in the hyper-contractility seen clinically in hypertrophic cardiomyopathy (HMC) patients.

这项工作使他的实验室目前在斯坦福大学专注于人类心脏肌节以及肥厚型和扩张型心肌病的分子基础。Spudich博士在2015年假设，大多数肥厚型心肌病突变可能会将β-心肌肌球蛋白头部从隔离的关闭状态转移到活跃的开启状态，以与肌动蛋白相互作用，从而导致临床上肥厚型心肌病（HMC）患者出现超收缩。

This unifying hypothesis is different from earlier prevailing views, and this viewing an old disease in a new light has become the favored view in the field of the molecular basis of hypercontractility caused by HCM mutations. Dr. Spudich has given more than 50 named lectureships and keynote addresses and has received many honors, including election to the National Academy of Sciences and recipient of the Albert Lasker Basic Medical Research Award.

这种统一的假设不同于早期流行的观点，从新的角度看待旧疾病已成为HCM突变引起的超收缩分子基础领域的热门观点。Spudich博士已经发表了50多篇演讲和主题演讲，并获得了许多荣誉，包括当选美国国家科学院院士和阿尔伯特·拉斯克基础医学研究奖获得者。

He is credited with co-founding MyoKardia Inc, which was acquired by Bristol Myers Squibb for $13.1 billion in 2020, and Cytokinetics, Inc., a late-stage, specialty cardiovascular biopharmaceutical company. Dr. Spudich received a Ph.D. in Biochemistry from Stanford University, in addition to completing his postdoctoral work in Genetics at Stanford University and in Structural Biology at the MRC Laboratory at Camb.

2020年，百时美施贵宝以131亿美元收购了MyoKardia Inc.和Cytokinetics，Inc.，后者是一家晚期专业心血管生物制药公司。Spudich博士在斯坦福大学获得了生物化学博士学位，此外还完成了斯坦福大学遗传学和剑桥大学MRC实验室结构生物学的博士后工作。

Quince’s SAB will provide expert insight and advice to support the advancement of the company’s lead asset, EryDex, targeting A-T, which is expected to begin enrollment for its pivotal Phase 3 clinical trial in the second quarter of 2024. The SAB also will be a valuable resource as Quince looks to strategically expand its development pipeline to include additional potential rare disease indications for EryDex, as well as additional potential applications of its AIDE technology platform targeting rare and debilitating disease programs..

Quince的SAB将提供专家见解和建议，以支持该公司领先资产EryDex的发展，该资产针对A-T，预计将于2024年第二季度开始注册其关键的3期临床试验。SAB也将是一个宝贵的资源，因为Quince希望战略性地扩大其开发渠道，以包括EryDex的其他潜在罕见疾病适应症，以及针对罕见和衰弱疾病计划的AIDE技术平台的其他潜在应用。。

About Quince Therapeutics

关于Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X..

Quince Therapeutics（纳斯达克股票代码：QNCX）是一家晚期生物技术公司，致力于挖掘患者自身生物学的潜力，为患有罕见疾病的患者提供创新和改变生命的疗法。有关该公司及其最新消息的更多信息，请访问www.quincetx.com，并在社交媒体平台LinkedIn、Facebook和Twitter/X上关注Quince Therapeutics。。

Forward-looking Statements

前瞻性声明

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections.

本新闻稿中的声明包含《1995年私人证券诉讼改革法》（见修订后的《1933年证券法》第27A节）和修订后的《1934年证券交易法》第21E节）所指的“前瞻性声明”，这些声明受这些条款所设“安全港”的约束。

All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words.

除历史事实陈述外，所有陈述都可能是前瞻性陈述。本新闻稿中包含的前瞻性陈述可以通过使用“相信”、“可能”、“应该”、“期望”、“预期”、“计划”、“相信”、“估计”、“潜在”、“打算”、“将会”、“可以”、“寻求”或其他类似词语来识别。

Examples of forward-looking statements include, among others, statements relating to current and future clinical development of EryDex, expansion of the company’s proprietary autologous intracellular drug encapsulation (AIDE) technology for treatment of other rare diseases, and benefits and impact of Quince’s Scientific Advisory Board.

前瞻性声明的例子包括与EryDex当前和未来临床开发有关的声明，公司专有自体细胞内药物包封（AIDE）技术用于治疗其他罕见疾病的扩展，以及Quince科学顾问委员会的益处和影响。

Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

前瞻性陈述基于Quince当前的预期，并受到难以预测的固有不确定性、风险和假设的影响，并可能导致实际结果与公司预期存在重大差异。此外，某些前瞻性陈述基于对未来事件的假设，这些假设可能不准确。

Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 14, 2023, and other reports as filed with the SEC.

可能导致实际结果产生差异的因素包括但不限于公司于2023年11月14日向美国证券交易委员会（SEC）提交的10-Q表季度报告中标题为“风险因素”的部分所述的风险和不确定性，以及向SEC提交的其他报告。

Forward-looking statements contained in this news release are ma.

本新闻稿中包含的前瞻性声明是ma。

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222393006/en/

在businesswire.com上查看源版本：https://www.businesswire.com/news/home/20240222393006/en/

Contacts

联系人

Media & Investor Contact:

媒体和投资者联系人：

Stacy Roughan

斯泰西·劳根

Quince Therapeutics, Inc.

昆斯治疗公司。

Vice President, Corporate Communications & Investor Relations

公司传播与投资者关系副总裁

ir@quincetx.com

ir@quincetx.com

Source: Quince Therapeutics, Inc.

来源：Quince Therapeutics，Inc。

View this news release online at:

在线查看此新闻稿，网址为：

http://www.businesswire.com/news/home/20240222393006/en

http://www.businesswire.com/news/home/20240222393006/en